NeoGenomics, Inc. (NEO) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $11.52: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: Below-average business quality.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical... Read more
Sell if holding. Engine safety override at $11.52: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: Below-average business quality. Chart setup: Death cross but MACD improving, RSI 83. Score 6.0/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — NeoGenomics, Inc.
Latest news
- NEWS NeoGenomics To Showcase Eight Scientific Abstracts, Highlighting Advances In MRD, Precision Oncology, And Real-World Evi — benzinga May 26, 2026 positive
- NEWS Earnings Scheduled For May 12, 2026 — benzinga May 12, 2026 neutral
- NEWS Benchmark Upgrades NeoGenomics to Buy, Announces $11 Price Target — benzinga Apr 29, 2026 positive
- NEWS TD Cowen Maintains Buy on NeoGenomics, Raises Price Target to $14 — benzinga Apr 29, 2026 positive
- NEWS Leerink Partners Upgrades NeoGenomics to Outperform, Raises Price Target to $25 — benzinga Apr 29, 2026 positive
Generated 2026-06-09T22:16:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -13.3%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.52: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: Below-average business quality. Chart setup: Death cross but MACD improving, RSI 83. Prior stop was $10.64. Score 6.0/10, moderate confidence.
Take-profit target: $13.10 (+14.5% upside). Prior stop was $10.64. Stop-loss: $10.64.
Quality below floor (3.5 < 4.0).
NeoGenomics, Inc. trades at a P/E of N/A (forward 30.0). TrendMatrix value score: 7.6/10. Verdict: Sell.
16 analysts cover NEO with a consensus score of 3.9/5. Average price target: $15.
What does NeoGenomics, Inc. do?NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United...
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.